アミリンとレニン- 血管新生系: アミリンベースの治療におけるリスクかチャンスか?
Marcel H A Muskiet1, Massimo Nardone2, Patrick C N Rensen3
1Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, Netherlands; Diabetes Centre, Department of Internal Medicine, Amsterdam University Medical Center, Amsterdam, Netherlands; Department of Medicine, Division of Nephrology, University Health Network, Toronto General Hospital Research Institute, Toronto, ON, Canada.
Lancet (London, England)
|November 9, 2025
まとめ
アミリン受容体アゴニストはレニン- 血管新生系 (RAS) を活性化させる可能性があります. これらの薬とRAS阻害剤を併用すると,保護経路への活性化を誘導することで,心肺神経の効果が向上する可能性があります.
科学分野:
- 内分泌学
- 心血管科学
- 代謝障害
背景:
- アミリン受容体アゴニストは肥満と2型糖尿病の治療法として開発されています.
- これらの治療はレニン- 血管新生系 (RAS) を活性化させ,心臓・腎臓の効果に影響を与える可能性があります.
- 新しいアミリンベースの治療法では 血圧が逆説的に低下しています
研究 の 目的:
- アミリン受容体アゴニストとRASの相互作用を調査する.
- RAS阻害剤がアミリンベースの治療法の有効性および心血管/腎臓の保護力を高めるかどうかを判断する.
- これらの効果を媒介する代替RAS経路 (Mas受容体) の役割を調査する.
主な方法:
- アミリン- RASの相互作用に関する臨床前試験
- RAS阻害剤の使用によって分層化された臨床試験のポストホック分析.
- バイオマーカー研究 (レニン,アルドステロン,アンジオテンシン-1~7),ACE2および機械的ヒト研究.
主要な成果:
- アミリンアゴニストによるRASの仮説的活性化
- RAS阻害剤による保護的なMAS受容体経路へのRAS活性化の潜在的転向.
- 新世代のアミリンベースの治療法では,血圧の大幅な低下が観察されました.
結論:
- RAS抑制は,アミリンベースの治療の治療効果を高める可能性があります.
- RAS阻害剤の併用は,心肺疾患のアウトカムを改善する可能性があります.
- これらの相互作用を確認し,臨床勧告を導くために,さらなる研究が必要である.
関連する概念動画
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
902
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
902
01:24Glucagon-like Receptor Agonists
828
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
828
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.3K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.3K
01:33Hormonal Regulation
35.7K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
35.7K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.4K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.4K